Loading

Please wait...

Xigduo Xr

Xigduo xr Prescription
Generic Name: dapagliflozin and metformin (DAP a gli FLOE zin and met FOR min)
Brand Names: Xigduo XR
Xigduo XR (dapagliflozin and metformin) is used to treat type 2 diabetes. Includes Xigduo XR side effects, interactions and indications.
  • Prescription Settings
  • X
  • medly Free, same-day prescription delivery to your doorstep is available in your area.
  • Learn more
  • Local Pharmacy Pickup available at . Pick up your medication at any of our participating pharmacies.
  • Mail Order Home Delivery available at , the easiest way to receive your medications.

Xigduo Xr Coupons & Prices

Set your location
for drug prices near you

Enter your zip code

Please wait while the prices are loaded...
Click here to try again.

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Xigduo Xr Drug Information:

Xigduo XR extended release tablets contain a combination of dapagliflozin and metformin. Dapagliflozin and metformin are oral Diabetes medicines that help control blood sugar levels. Dapagliflozin works by helping the kidneys get rid of glucose from your bloodstream. Metformin lowers glucose production in the liver and also causes your intestines to absorb less glucose. Xigduo XR is used together with diet and exercise to improve blood sugar control in adults with type 2 Diabetes mellitus. Xigduo XR is not for treating type 1 Diabetes. Learn more

Buy Xigduo xr Online and Xigduo xr Delivery

USARx offers the following ways to purchase this medication. Choose the Best option for you!

  • Guaranteed Price

    Local Pharmacy Pickup of Xigduo xr

    Pay this amount and pick up your prescription at ANY Retail pharmacy of your choice! Walgreens, CVS, Walmart, etc.

  • 30-day supply
    90-day supply

    Mail Order Home Delivery of Xigduo xr

    The easiest way to receive your medications.

Xigduo Xr Side Effects

Note: This document contains side effect information about dapagliflozin / metformin. Some of the dosage forms listed on this page may not apply to the brand name Xigduo XR.

In Summary

Common side effects of Xigduo XR include: lactic acidosis. Other side effects include: cystitis, pyelonephritis, urinary tract infection, vulvovaginal candidiasis, bacterial vaginosis, genital candidiasis, genitourinary infection, nasopharyngitis, prostatitis, urethritis, vaginal infection, vulvitis, vulvovaginitis, nausea, and vomiting. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to dapagliflozin / metformin: oral tablet extended release

Warning

Oral route (Tablet, Extended Release)

Fatal metformin-associated lactic acidosis has been reported during postmarketing surveillance. The onset is often subtle and subtle and accompanied only by nonspecific symptoms (eg, malaise, myalgias, respiratory distress, somnolence, abdominal pain). Risk factors include concomitant carbonic anhydrase inhibitor use (eg, topiramate), age 65 or older, surgery and other procedures, radiological study with contrast, hypoxic states, excessive alcohol consumption, or hepatic impairment. If suspected, discontinue use and initiate hemodialysis and general supportive measures.

Along with its needed effects, dapagliflozin/metformin may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking dapagliflozin / metformin:

More common

  • Bladder pain
  • bloody or cloudy urine
  • change in the color, amount, or odor of vaginal discharge
  • difficult, burning, or painful urination
  • frequent urge to urinate
  • lower back or side pain

Rare

  • Abdominal or stomach discomfort
  • decreased appetite
  • diarrhea
  • fast, shallow breathing
  • general feeling of discomfort
  • large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
  • muscle pain or cramping
  • nausea
  • shortness of breath
  • sleepiness
  • unusual tiredness or weakness

Incidence not known

  • Anxiety
  • blurred vision
  • chills
  • cold sweats
  • coma
  • confusion
  • cool, pale skin
  • depression
  • dizziness
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • fast heartbeat
  • fever
  • headache
  • hives, itching, or rash
  • hoarseness
  • increased hunger
  • irritation
  • joint pain, stiffness, or swelling
  • nightmares
  • redness of the skin
  • seizures
  • shakiness
  • slurred speech
  • sweating
  • swelling of the eyelids, face, lips, hands, or feet
  • tightness in the chest
  • troubled swallowing

Some side effects of dapagliflozin / metformin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Muscle aches
  • sore throat
  • stuffy or runny nose

Less common

  • Back pain
  • body aches or pain
  • congestion
  • difficulty having a bowel movement (stool)
  • tender, swollen glands in the neck
  • voice changes

For Healthcare Professionals

Applies to dapagliflozin / metformin: oral tablet extended release

General

The most common adverse reactions reported with this combination drug included female genital mycotic infection, nasopharyngitis, urinary tract infection, diarrhea, and headache.

Metabolic

Hypoglycemia was reported more frequently when this drug was added to sulfonylurea or insulin (up to 43%). Hypoglycemia was not reported in dapagliflozin monotherapy trials, and was reported infrequently in add-on trials with metformin, or dipeptidyl peptidase-4 inhibitors.

Twenty reports of acidosis have been identified in the US Food and Drug Administration Adverse Event Reporting System (FAERS) database during the period March 2013 through 06 June 2014. All patients required emergency room treatment or hospitalization. These cases were not typical of ketoacidosis or diabetic ketoacidosis (DKA) in that they occurred in patients with type 2 diabetes and their blood sugar levels were only slightly increased. Some factors identified as potentially triggering the acidosis included major illness, reduced food and fluid intake, and reduced insulin dose.

Dapagliflozin-Metformin:

Very common (10% or more): Hypoglycemia (when used with sulfonylurea or insulin)

Dapagliflozin:

Common (1% to 10%): Hyperphosphatemia, increases in low-density lipoprotein cholesterol (LDL-C)

Uncommon (0.1% to 1%): Decreased weight, thirst

Postmarketing reports: Acidosis including diabetic ketoacidosis, ketoacidosis, or ketosis

Metformin:

Very rare (less than 0.01%): Lactic acidosis, vitamin B12 deficiency

Gastrointestinal

Dapagliflozin-Metformin:

Common (1% to 10%): Diarrhea, nausea, constipation

Dapagliflozin:

Uncommon (0.1% to 1%): Constipation, dry mouth

Metformin:

Very common (10% or more): Gastrointestinal symptoms such as nausea, vomiting, diarrhea, abdominal pain, and loss of appetite occurring most frequently during initiation

Cardiovascular

Uncommon (0.1% to 1%): Adverse reactions related to reduced intravascular volume (dehydration, hypovolemia, orthostatic hypotension, or hypotension)

Respiratory

Common (1% to 10%): Nasopharyngitis, cough, pharyngitis

Dermatologic

Dapagliflozin:

Postmarketing reports: Rash

Metformin:

Very rare (less than 0.01%): Urticaria, erythema, pruritus

Endocrine

Small increases in serum parathyroid hormone (PTH) levels were observed with increases larger in subjects with higher baseline PTH concentrations. Bone mineral density in patients with normal or mildly impaired renal function did not indicate bone loss over a period of 2 years.

Dapagliflozin:

Frequency not reported: Small increases in serum parathyroid hormone levels

Oncologic

Dapagliflozin:

Uncommon (0.1% to 1%): Bladder cancer

Newly diagnosed bladder cancer was reported in 10 of 6045 (0.17%) patients receiving dapagliflozin in clinical trials compared with 1 of 3512 (0.3%) patients receiving placebo or comparator. Upon excluding patients in whom exposure to study drug was less than 1 year at time of diagnosis, there were no cases associated with placebo and 4 cases with this drug. Due to the low number of cases, further studies are needed.

Genitourinary

Common (1% to 10%): Female genital mycotic infections (including vulvovaginal mycotic infection, vaginal infection, genital infection, vulvovaginitis, fungal genital infection, vulvovaginal candidiasis, vulval abscess, genital candidiasis, and vaginitis bacterial), urinary tract infections (including urinary tract infection cystitis, pyelonephritis, urethritis, and prostatitis), male genital mycotic infections (including balanitis, fungal genital infection, balanitis candida, genital candidiasis, balanoposthitis, balanoposthitis infective, genital infection, posthitis), increased urination, discomfort with urination

Uncommon (0.1% to 1%): Vulvovaginal pruritus

Postmarketing reports: Fournier's gangrene

Genital mycotic infections have been commonly reported with dapagliflozin treatment. Discontinuation due to genital infection occurred in 0.2% of patients in dapagliflozin clinical trials. Infections were more frequently reported in females than males, and patients with a history of genital mycotic infections were more likely to have an infection than those without a history.

In the 5 years (2013 to 2018) since SGLT2 inhibitor approval, 12 cases of Fournier's gangrene have been reported. Reports were almost equal in men and women (men=7; women=5), ages ranged from 38 to 78 years, and the average time to onset after starting an SGLT2 inhibitor was 9.2 months (range 7 days to 25 months). All SGLT2 inhibitor drugs except ertugliflozin were included in the reports. Ertugliflozin being the most recently approved agent, is expected to have the same risk, but insufficient patient use to assess risk. All patients were hospitalized, all required surgery, all required surgical debridement, 5 required more than 1 surgery and 1 required skin grafting. Four cases were complicated by diabetic ketoacidosis, acute kidney injury, and septic shock, leading to prolonged hospitalization, and death in 1 case. In the general population, Fournier's gangrene occurs in about 1.6 out of 100,000 males annually, with the highest incidence in men 50 to 79 years. Since diabetes is a risk factor for Fournier's gangrene, a review of the FAERS database for the last 34 years was done and only 6 cases (all males, median age 57 years) were found with several other classes of antidiabetic drugs. Findings with SGLT2 inhibitors appear to show an association over a shorter time frame and involve both males and females.

Hematologic

Dapagliflozin:

Common (1% to 10): Hematocrit increased

Metformin:

Very rare (less than 0.01%): Decreased vitamin B12 serum levels

Hepatic

Metformin:

Very rare (less than 0.01%): Liver function disorders, liver function tests abnormalities, hepatitis

Postmarketing reports: Cholestatic, hepatocellular, and mixed hepatocellular liver injury

Hypersensitivity

Dapagliflozin:

Rare (less than 0.1%): Serious anaphylactic reactions, severe cutaneous reactions, and angioedema

Musculoskeletal

Common (1% to 10%): Back pain

Nervous system

Dapagliflozin-Metformin:

Common (1% to 10%): Headache, dizziness,

Metformin:

Common (1% to 10%): Taste disturbance

Renal

Dapagliflozin:

Uncommon (0.1% to 1%): Increased serum creatinine, blood urea increased

Frequency not reported: Decreases in eGFR

Postmarketing reports: Acute kidney injury and impaired renal function

Cases of acute kidney injury have been reported during the postmarketing period with dapagliflozin. Some cases required hospitalization and dialysis; some reports were in patients less than 65 years old.

Immunologic

Common (1% to 10): Influenza

Editorial References and Review

Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.

Source: Drugs.com Xigduo Xr (www.drugs.com/xigduo-xr.html).